IP Library Patent Application 14696836
Patent Application
App. No. 14/696,836

TREATMENT OF LEG ULCERS USING PLACENTA DERIVED COLLAGEN BIOFABRIC

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/696,836
Abstract

The present invention provides a method of treating a leg ulcer comprising contacting the leg ulcer with a collagen biofabric. The leg ulcer may be a venous, arterial, diabetic or decubitus (pressure) ulcer. The invention further provides kits comprising one or more pieces of collagen biofabric for the treatment of a leg ulcer.

Claims (21)

1 .- 24 . (canceled)

25 . A sterilized, decellularized, and dehydrated amnion-derived biofabric, wherein said biofabric is coated with or impregnated with granulocyte macrophage stimulating factor (GM-CSF).

26 . The biofabric of claim 25 , wherein said biofabric comprises native vascular-endothelial growth factor (VEGF) and fibroblast growth factor (FGF).

27 . A pharmaceutical composition comprising the biofabric of claim 25 .

28 . A pharmaceutical composition comprising the biofabric of claim 26 .

29 . The biofabric of claim 25 , wherein said biofabric is shaped as a sheet or membrane.

30 . The biofabric of claim 29 , wherein said biofabric is shaped as a sheet.

31 . The biofabric of claim 25 , wherein said biofabric is shaped as a netting or webbing.

32 . The biofabric of claim 25 , wherein said biofabric is mounted on a support.

33 . The biofabric of claim 32 , wherein said support is a bandage.

34 . A method of treating a leg ulcer, comprising contacting said ulcer with the collagen biofabric of claim 25 .

35 . The method of claim 34 , wherein said contacting improves at least one aspect of the leg ulcer, or prevents or reduces the worsening of at least one aspect of a leg ulcer.

36 . The method of claim 34 , wherein said contacting is for a time sufficient for at least one aspect of the leg ulcer to measurably improve compared to a leg ulcer not contacted with the collagen biofabric.

37 . The method of claim 34 , wherein said contacting is for a time sufficient to prevent or reduce the worsening of at least one aspect of said leg ulcer.

38 . The method of claim 34 , wherein said leg ulcer is a venous leg ulcer, arterial leg ulcer, diabetic leg ulcer, or decubitus ulcer.

39 . The method of claim 38 , wherein said leg ulcer is a venous leg ulcer.

40 . The method of claim 34 , wherein said contacting comprises placing the collagen biofabric on the leg ulcer so that substantially all of the surface area of the biofabric contacts the leg ulcer.

41 . A kit for the facilitation of the treatment of leg ulcers, comprising the collagen biofabric of claim 25 .

42 . The kit of claim 41 , further comprising a medical device, disposable or drug that facilitates treatment of a leg ulcer.

43 . The kit of claim 41 , wherein the collagen biofabric is provided as a single sheet or patch in a sterile container or wrapping.

44 . The kit of claim 41 , further comprising an anti-infective agent and/or a wound healing agent.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 9, 2017
From: CLARITY ACQUISITION II LLC
To: CELULARITY, INC.
Reel/Frame 044780/0261 →
MERGER Recorded Nov 8, 2017
From: ANTHROGENESIS CORPORATION
To: CLARITY ACQUISITION II LLC
Reel/Frame 044413/0680 →